CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in- class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study. Results of this study will allow the selection of doses for pivotal Phase III studies of lasmiditan in the acute treatment of migraine, scheduled to begin in fourth quarter this year.
CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan in the treatment of acute migraine attacks
GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx
Fairfield, CT, USA – May 13, 2010 — GE Healthcare, the healthcare business of GE (NYSE: GE) and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease. Building on the alliance, the GE Healthymagination Fund, a new equity fund that makes investments in highly promising healthcare technology companies, has invested $5 million in CardioDx as part of a Series D round that the fund is leading. The alliance between the two companies aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare. This marks the first investment for the HealthymaginationFund. Otherfinancialtermswerenotdisclosed.
GE Healthcare forms strategic alliance with cardiovascular genomic diagnostic company, CardioDx
GE Healthcare, the healthcare business of GE (NYSE: GE) and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease. Building on the alliance, the GE Healthymagination Fund (www.healthymaginationfund.com), a new equity fund that makes investments in highly promising healthcare technology companies, has invested $5 million in CardioDx as part of a Series D round that the fund is leading. The alliance between the two companies aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare. This marks the first investment for the HealthymaginationFund. Otherfinancialtermswerenotdisclosed.
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
MONMOUTH JUNCTION, N.J., April 27, 2010 --(BUSINESS WIRE)-- TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST , its antibacterial product for the surgical repair of damaged or ruptured soft tissue.
TYRX had previously received 510(k) clearance to market a product for hernia repair and other abdominal soft tissue deficiencies. The new clearance adds the use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue. AIGISRx ST delivers the antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST , its antibacterial product for the surgical repair of damaged or ruptured soft tissue.
Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
RESEARCH TRIANGLE PARK, N.C., April 20, 2010 --(EON: Enhanced Online News)-- Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
Liquidia Technologies has added an additional investor, PPD, Inc., to its Series C financing
Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million. The initial Series C closing was announced in January 2010.
Cequent begins chronic toxicology study
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26- week) toxicology study of CEQ508 – the company’s lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer. The non-human primate (NHP) study will evaluate safety and gene knock-down with once-daily oral administration of CEQ508. As an addition to this study, Cequent has begun dosing with the therapeutic candidate optioned by Novartis to enable an upcoming IND application in inflammatory bowel disease (IBD).
New Anti-Bacterial Device Helps Reduce Infections Associated with Pacemaker and Defibrillator Implantation
Monmouth Junction, NJ, (April 13, 2010) -- TYRX, Inc. announced today the commercial release of the AIGISRx® Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.
Like the original AIGISRx™ Envelope, AIGISRx Flat delivers the anti-microbial agents, rifampin and minocycline which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm management device (CRMD)-related endocarditis, including “superbugs” or MRSA. AIGISRx Flat also offers the implanting physician additional flexibility in the application of these lifesaving devices.
TyRx announces commercial release of the AIGISRx™ Flat
TYRX, Inc. announced today the commercial release of the AIGISRx® Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.
